231 related articles for article (PubMed ID: 18942395)
21. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
22. Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas.
Somorácz A; Tátrai P; Horváth G; Kiss A; Kupcsulik P; Kovalszky I; Schaff Z
Hum Pathol; 2010 Sep; 41(9):1310-9. PubMed ID: 20471664
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of expressions of Arg-1, Hep Par-1, and CK19 in the diagnosis of the primary hepatocellular carcinoma subtypes and exclusion of the metastases.
Atta IS
Histol Histopathol; 2021 Sep; 36(9):981-993. PubMed ID: 34254284
[TBL] [Abstract][Full Text] [Related]
24. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver.
Lei JY; Bourne PA; diSant'Agnese PA; Huang J
Am J Clin Pathol; 2006 Apr; 125(4):519-25. PubMed ID: 16627262
[TBL] [Abstract][Full Text] [Related]
25. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.
Radwan NA; Ahmed NS
Diagn Pathol; 2012 Oct; 7():149. PubMed ID: 23111165
[TBL] [Abstract][Full Text] [Related]
26. Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma.
Yuan RH; Jeng YM; Hu RH; Lai PL; Lee PH; Cheng CC; Hsu HC
J Gastrointest Surg; 2011 Feb; 15(2):321-9. PubMed ID: 21061181
[TBL] [Abstract][Full Text] [Related]
27. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
[TBL] [Abstract][Full Text] [Related]
28. Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas.
Imai Y; Oda H; Arai M; Shimizu S; Nakatsuru Y; Inoue T; Ishikawa T
Jpn J Cancer Res; 1996 Oct; 87(10):1056-62. PubMed ID: 8957064
[TBL] [Abstract][Full Text] [Related]
29. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma.
Ushiku T; Shinozaki A; Shibahara J; Iwasaki Y; Tateishi Y; Funata N; Fukayama M
Am J Surg Pathol; 2010 Apr; 34(4):533-40. PubMed ID: 20182341
[TBL] [Abstract][Full Text] [Related]
30. Combined hepatocellular-cholangiocarcinoma. Cytologic findings in four cases.
Dusenbery D
Acta Cytol; 1997; 41(3):903-9. PubMed ID: 9167724
[TBL] [Abstract][Full Text] [Related]
31. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas.
Ohashi R; Gao C; Miyazaki M; Hamazaki K; Tsuji T; Inoue Y; Uemura T; Hirai R; Shimizu N; Namba M
Anticancer Res; 2001; 21(1B):657-62. PubMed ID: 11299822
[TBL] [Abstract][Full Text] [Related]
32. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas.
Borscheri N; Roessner A; Röcken C
Am J Surg Pathol; 2001 Oct; 25(10):1297-303. PubMed ID: 11688465
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
34. [An immunohistochemical study on primary carcinoma of the liver].
Seo JK
J UOEH; 1989 Dec; 11(4):429-39. PubMed ID: 2481871
[TBL] [Abstract][Full Text] [Related]
35. Cytokeratin19 positive hepatocellular carcinoma is associated with increased peritumoral ductular reaction.
Cai X; Feng L; Liu H; Xu M; Qu Y; Wan X; Gao C; Lu L
Ann Hepatol; 2016; 15(3):386-93. PubMed ID: 27049492
[TBL] [Abstract][Full Text] [Related]
36. Expression of smooth muscle calponin in tumor vessels of human hepatocellular carcinoma and its possible association with prognosis.
Sasaki Y; Yamamura H; Kawakami Y; Yamada T; Hiratsuka M; Kameyama M; Ohigashi H; Ishikawa O; Imaoka S; Ishiguro S; Takahashi K
Cancer; 2002 Mar; 94(6):1777-86. PubMed ID: 11920541
[TBL] [Abstract][Full Text] [Related]
37. Expression and clinical significance of the G1-S modulators in intrahepatic cholangiocellular carcinoma.
Ito Y; Takeda T; Sasaki Y; Sakon M; Yamada T; Ishiguro S; Imaoka S; Tsujimoto M; Matsuura N
Oncology; 2001; 60(3):242-51. PubMed ID: 11340376
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics.
Wee A
Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):266-72. PubMed ID: 16932016
[TBL] [Abstract][Full Text] [Related]
39. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.
Qin LX; Tang ZY
J Cancer Res Clin Oncol; 2004 Sep; 130(9):497-513. PubMed ID: 15205947
[TBL] [Abstract][Full Text] [Related]
40. Glypican-3 is useful but not superior to Hep Par 1 in differentiating hepatocellular carcinoma from other liver tumours.
Pour AM; Masir N; Rose IM
Malays J Pathol; 2016 Dec; 38(3):229-233. PubMed ID: 28028292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
